Articles tagged with Clinical Trials
A phase 2 clinical trial found that burosumab safely restored normal phosphate levels and improved physical function in patients with severe fibrous dysplasia. Key findings include reduced pain, fatigue, and mobility impairment, as well as significant improvements in children's mobility and independence.
Interleukin 6 is investigated as a treatment target for depression in this randomized clinical trial. The study highlights the therapeutic potential of IL-6 or IL-6 receptor inhibition and proposes suitable patient selection methods.
A University of Bristol-led pilot trial found that tocilizumab reduced symptoms of depression, fatigue and anxiety in people who had not responded to standard treatments. The study provides early evidence for a new treatment option for patients with inflammation-related depression.
A clinical trial found that a remote multicomponent rehabilitation programme can improve quality of life for patients recovering from intensive care, particularly those ventilated for shorter periods. The online intervention combined symptom management, exercise, psychological support, and peer information, offering hope for better rec...
A new study presents tezepelumab as a safe and effective treatment for severe asthma in underrepresented populations. The therapy reduces exacerbations by 70% and improves lung function, quality of life scores, and asthma control. It is particularly effective in patients with Type 2 asthma and those with comorbid COPD.
A post hoc analysis of a randomized clinical trial found high-dose vitamin D3 supplementation in pregnancy to be positively associated with visual memory, verbal memory, and flexibility among offspring at age 10. This strengthens evidence on the association between prenatal vitamin D exposure and childhood cognition.
A systematic review and meta-analysis found that creatine supplementation does not significantly reduce inflammatory markers in the body. Despite its ergogenic effects on physical performance, creatine's anti-inflammatory properties are limited to specific contexts, such as intense exercise.
A nationwide trial found that giving whole blood or its component parts to patients with severe bleeding before arriving at the hospital is equally effective. The study, which included over 1,000 patients, also showed no difference in outcomes between newer and older blood within a certain time frame.
Researchers found that stereotactic body radiotherapy (SBRT) improved progression-free survival by 15.6 months, compared to 20.6 months without targeted therapy. The treatment also showed no significant impact on quality-of-life measures.
Researchers at Winship Cancer Institute have administered the first investigational in vivo CAR-T cell therapy in the US for relapsed and refractory multiple myeloma, marking a significant milestone in next-generation cellular therapies. The therapy aims to streamline treatment processes and eliminate delays in care.
A cohort study found a potential association between GLP-1 RA use and improved survival rates among obese breast cancer patients with related metabolic conditions. Further evaluation of GLP-1 RA therapy in randomized clinical trials is warranted based on these findings.
A new post-hoc analysis examined daily oral orforglipron treatment for obesity, with or without diabetes, in users aged 65 years and over. The study found that orforglipron significantly reduced body weight and improved blood sugar markers compared to placebo, with a similar safety profile to the overall ATTAIN clinical trial population.
A pooled analysis of trials reveals semaglutide's safety and efficacy in individuals aged 65 years and older with obesity. The study found significant reductions in body weight and improvements in cardiometabolic risk factors, with a lower proportion of adverse events compared to placebo.
A randomized clinical trial found that genotype-guided prescribing of SSRIs did not improve depression symptoms at 3 months but showed higher remission rates at 6 months. Future studies should focus on the long-term impact of this approach.
The ERASur clinical trial is investigating whether total ablative therapy can improve overall survival in patients with newly diagnosed, limited metastatic colorectal cancer. The study has reached one-third patient accrual milestone, signaling strong momentum.
A phase 1/2 trial of daraxonrasib, a RAS(ON) multi-selective inhibitor, demonstrated safety and broad activity against RAS-mutant metastatic pancreatic cancer. The drug showed promising signs of activity, with approximately 30% of patients experiencing an objective response and 90% experiencing disease control.
The International Progressive MS Alliance has launched the MS Clinical and Imaging Data Resource (MS CIDR) to accelerate understanding of MS progression. The resource contains anonymized data from 14 pharmaceutical industry clinical trials, including MRI scans and clinical visits data from over 13,000 people with progressive MS.
Recent shifts in federal policy and funding have impacted hundreds of clinical trials designed to study disease burdens in underrepresented populations. The report highlights a systemic crisis in medical research, citing a disruption at scale that has affected over 74,000 participants across 383 trials.
The ASPIRE trial aims to enroll 1,200 participants with advanced prostate cancer and assess the impact of chemotherapy on overall survival and disease progression. Genetic profiling is included to identify patients who benefit most from intensified treatment.
The Blanke Veterans Access to Cancer Trials Initiative aims to increase veteran participation in NCI-supported clinical trials. With more than a decade of progress, the initiative builds on grants and federal investments to strengthen Veterans Affairs Medical Center participation.
The INS001-055 inhalation solution is the world's first AI-driven candidate to receive IND clearance. It targets Idiopathic Pulmonary Fibrosis (IPF) with a novel molecule structure and demonstrates good tolerability, PK profiles, and dose-dependent efficacy trend.
EGFR-TKIs have significantly improved OS and quality of life for EGFR-mutant NSCLC patients. However, ongoing research is needed to refine therapies for precise individualized treatment, addressing resistance mechanisms and optimal combination strategies.
Independent academic clinical trials are essential for improving patient outcomes, reducing inequalities in care, and strengthening healthcare systems. The Lancet Oncology Commission aims to deliver actionable recommendations to ensure these trials continue to benefit patients and society worldwide.
A randomized clinical trial found that proactive outreach for care coordination did not lead to better outcomes compared to usual care post-hospitalization coordination. Many participants declined the offer. The study suggests that current strategies may need to be reassessed.
A UK-led trial found that a procedure to reopen blocked heart arteries can reduce chest pain and improve quality of life. Patients who received the treatment had more angina-free days and better quality-of-life scores than those in the placebo group.
A randomized clinical trial found symptom-based dosing decreases discharge time compared to scheduled opioid taper approaches among infants with opioid withdrawal. This approach, using Eat, Sleep, Console, led to faster recovery and improved outcomes.
The Keck School of Medicine of USC and Tempus are creating a system-wide framework to integrate clinical care, clinical trials, and research through AI-powered precision medicine tools. The goal is to enhance patient care and accelerate research and innovation.
A phase 1 clinical trial has started enrolling patients with symptoms of prion disease, evaluating the safety and tolerability of a small interfering RNA targeting the prion protein. The trial aims to slow disease progression and is supported by NeuroNEXT, a program of the National Institute of Neurological Disorders and Stroke.
Recent studies have explored tumor vaccine platforms, including peptide, dendritic cell, and nucleic acid-based vaccines. Personalized neoantigen vaccines are refining precision in HCC treatment, but challenges persist due to immunosuppressive tumor microenvironments and heterogeneity.
Researchers discovered a powerful molecule called miR-181d that weaks tumors and helps the immune system fight back against glioblastoma. The study found that tumors in 'exceptional responders' contain higher levels of miR-181d, which blocks cancer cells' ability to repair DNA damage.
A video game developed to improve trauma triage decision making in emergency doctors has shown promising results. The game reduced under-triage rates for older patients by 49% compared to those who did not play the game, suggesting improved diagnostic abilities and adherence to guidelines.
A cluster-randomized trial found that an adaptive mobile health intervention effectively reduced the rate of gestational weight gain and total gestational weight gain among pregnant patients with overweight or obesity. The study suggests that technology-based interventions can be a valuable tool in managing excess weight during pregnancy.
A new trial found that proximal hypoglossal nerve stimulation (pHGNS) significantly reduced breathing interruptions during sleep and improved daytime sleepiness without adverse events. The therapy, an FDA-approved alternative to nasal positive airway pressure, was found to be safe and effective in patients with moderate-to-severe obstr...
A study by the Alliance Foundation Trials shows that combining immunotherapy and chemotherapy before surgery can help more patients with locally advanced non-small cell lung cancer undergo complete cancer resection, improving their long-term health. The treatment also led to high rates of lymph node clearance and successful surgical re...
The Phase I MYTHIC trial demonstrated a strong synergy between zedoresertib and lunresertib, showing durable regressions and consistent tumor shrinkage in patients with ovarian cancer. The combination achieved an overall disease control rate of 68.5% and a molecular response rate of 47%.
A first-in-human trial shows that an infusion of immune cells derived from a donor's blood can prime the recipient's immune system to accept a donor liver, potentially reducing lifelong immunosuppression. Eight out of 13 participants achieved complete withdrawal of immunosuppression and remained off for more than three years.
The JAMA+ Trials platform provides a comprehensive online space for clinical trial research, featuring multimedia content and tailored resources. Recent trials published across multiple JAMA Network journals are highlighted on the platform.
The hospital is conducting a phase 2 clinical trial evaluating STAR0602, which activates the immune system to stop tumor growth across various cancers. The goal of this study is to identify safer and more effective treatments for people with advanced cancers.
A phase 2 clinical trial shows that a new drug, elraglusib, when combined with chemotherapy, doubles one-year survival rates in pancreatic cancer patients, reducing the risk of death by 38%. The study is a rare success in showing a survival benefit applicable to a broad population.
A clinical trial aims to evaluate whether laser therapy reduces vaginal dryness caused by breast cancer treatment. The study, REVITALIZE, plans to enroll approximately 250 women with a history of breast cancer who experience moderate to severe vaginal dryness.
A new multicenter trial demonstrates that hepatologists trained in palliative care can deliver the same quality-of-life benefits as a palliative care specialist. Quality of life improved significantly in both groups, with symptom burden and short-term mortality comparable between groups.
A new clinical trial at the University of Cincinnati is testing a peptide solution to treat prosthetic joint infections after total knee replacement. The trial aims to reduce the need for repeat surgeries and expand the treatment window beyond two weeks.
A phase 2 clinical trial shows that mezagitamab can effectively increase platelet counts in patients with immune thrombocytopenia, improving quality of life. The investigational medication has a rapid effect, normalizing platelet counts in 48 hours.
A randomized trial found that duloxetine does not prevent painful neuropathy caused by oxaliplatin-based chemotherapy in patients with stage II or III colorectal cancer. The study suggests that duloxetine should only be used for managing existing neuropathy, not prevention.
The Alliance for Clinical Trials in Oncology is enrolling adolescent and young adult cancer patients in various trials, including genetic services and treatment studies. These trials aim to address longstanding gaps in care and improve outcomes for AYAs with cancer.
In this randomized clinical trial, mirtazapine effectively reduced methamphetamine use in adults with methamphetamine use disorder. The study's findings have important implications for the treatment of this condition, which currently lacks approved pharmacotherapies.
A phase 1/2 clinical study found that pralsetinib improved durable responses with manageable safety profiles in patients with advanced or metastatic RET fusion-positive non-small cell lung cancer. The overall response rate was 78% and median duration of response was longer in patients with the CCDC6-RET fusion gene.
A phase III clinical trial established a new treatment standard for patients with stage III colon cancer and deficient DNA mismatch repair. Immunotherapy drug atezolizumab showed significant benefits when added to chemotherapy, lowering the risk of cancer recurrence by 50%.
A nationwide Japanese trial found that catheter ablation did not reduce the risk of recurrent stroke or major cardiovascular events in patients with atrial fibrillation who had recently experienced a stroke. The study, which enrolled 251 patients and followed them for over three years, suggests that routine addition of catheter ablatio...
Dr. Roxana Mehran was appointed President of the American College of Cardiology, focusing on innovation, equity, and global collaboration to advance cardiovascular care. She aims to improve heart health for all through partnerships with major organizations.